A Danish company with a long-acting growth hormone medicine approved in Europe, which also runs cancer trials of a long-acting form of the immune signal interleukin-2.
Ascendis Pharma's oncology arm, Ascendis Pharma Oncology Division A/S, is the lead sponsor of two phase 1/2 studies on ClinicalTrials.gov. IL Believe (NCT05081609, started January 2022, active and no longer recruiting) tests TransCon IL-2 β/γ alone or with pembrolizumab, the TransCon TLR7/8 agonist, chemotherapy or trastuzumab-based treatment in advanced solid tumours, with cohorts listed for platinum-resistant ovarian cancer, melanoma after anti-PD-1 treatment, cervical cancer, non-small-cell and small-cell lung cancer and HER2-positive breast cancer. A study of the TransCon TLR7/8 agonist with or without pembrolizumab in advanced solid tumours (NCT04799054, started March 2021) is terminated. Outside cancer, the European Medicines Agency authorised its growth hormone medicine lonapegsomatropin (Skytrofa) for children and adolescents with growth hormone deficiency on 11 January 2022; the marketing authorisation holder, Ascendis Pharma Endocrinology Division A/S, is at Hellerup, Denmark.
Shares Cytokines & engineered cytokines, Melanoma.
Shares Cytokines & engineered cytokines, Melanoma, Non-small-cell lung cancer.
Shares Cytokines & engineered cytokines, Non-small-cell lung cancer.
Shares Cytokines & engineered cytokines, Non-small-cell lung cancer.
Shares Cytokines & engineered cytokines, Melanoma.
Shares Cytokines & engineered cytokines, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/